Uncategorised - European Medical Journal

Characterisation of Patients with Acute Coronary Syndrome: A 10-Year Experience

Coronary intervention is a therapeutic method for acute coronary syndrome. Characterise patients with acute coronary syndrome treated…

Adult Survivors of Childhood Cancer Have Significant Levels of Impaired Cardiorespiratory Fitness, Inflammatory Markers, and Poor Quality of Life Outcomes

Almost two-thirds of the 35,000 children diagnosed with cancer in Europe each year are treated with anthracycline chemotherapy. Despite…

Artificial Intelligence and Heart Failure

To emphasise the importance of this topic, Oguz Akbilgic, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA…

Risk Factors and Patterns of Myocardial Injury in Patients with COVID-19: A Single-Centre Cohort Study

The primary objective was to compare the risk factors and trends of patients with COVID-19 with and without biochemical evidence of…

ESC 2023 Abstract Highlights

The following selected highlights showcase intriguing and relevant abstracts presented at the European Society of Cardiology (ESC)…

PCSK9 Targeting in the Management of Hypercholesterolaemia

In the current era of optimal risk factor modification, proprotein convertase subtilisin/kexin type 9 (PCSK9) targeting has emerged as a…

Lennox–Gastaut Syndrome: Challenges in Diagnosis – Interviews with Two Key Opinion Leaders

Lennox–Gastaut syndrome (LGS) is a severe childhood-onset epilepsy syndrome that can be challenging to identify due to its heterogeneous and..

EASD 2023: Study Suggests Re-evaluation of Type 2 Diabetes Diagnosis Criteria for Women Under 50

Women with Type 2 diabetes face a higher mortality rate at a younger age than men, partly due to delayed diagnosis. A new study spotlights the need to reconsider T2D diagnosis criteria for pre-menopausal women under 50.

Taking the pulse of digital health

Parveen Jayia, Therapy Area Head, Breast and Gynaecological Cancers, AstraZeneca, talks to GOLD about the role digital health can play in the future of the industry.

ECCO 2022 Insights: Treatment developments for inflammatory bowel disease (IBD) and rheumatology

Explore the latest insights from ECCO 2022, which discusses the latest updates and emerging developments in the treatments of irritable bowel disease (IBD) and rheumatic diseases.